Axonics, Inc. is a medical technology company, which develops and commercializes products to treat bladder and bowel dysfunction. It has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10 cubic centimeters (cc) in volume, utilizes constant current stimulation, a recharge-free patient remote control and offers broad magnetic resonance imaging (MRI) access. Its SNM systems include an easy-to-use wireless patient remote control that does not require recharging or replacement batteries. It also offers a clinician programmer that guides the implanting physician through lead placement and stimulation programming.

Axonics Modulation Technologies Inc

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company's other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.

Gilead Sciences Inc.

Global X Lithium ETF (the Fund) seeks to provide investment results that correspond generally to the price and yield performance of the Solactive Global Lithium Index (the Index). The Index is free float adjusted, liquidity tested and market capitalization-weighted index that is designed to measure broad based equity market performance of global companies involved in the lithium industry, as defined by Structured Solutions AG. The Fund will normally invest at least 80% of its total assets in the securities of the Index and in depositary receipts based on the securities in the Index. The Fund will concentrate its investments (will hold 25% or more of its total assets) in a particular industry or group of industries to approximately the same extent that the Index is concentrated. The Index is sponsored by Structured Solutions AG, the index provider. The Fund’s investment adviser is Global X Management Company LLC.

Global X Lithium & Battery Tech ETF

Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer globally through the use of its proprietary tests, vast data sets and advanced analytics. The Company has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. It also has developed Guardant360 TissueNext tissue test for advanced-stage cancer, Guardant Reveal blood test to detect residual and recurring disease in early-stage cancer patients, and Guardant360 Response blood test to predict patient response to immunotherapy or targeted therapy eight weeks earlier than current standard-of-care imaging. The Company’s GuardantINFORM platform is used to help biopharmaceutical companies accelerate precision oncology drug development through the use of this in-silico research platform to unlock further insights into tumor evolution and treatment resistance across various biomarker-driven cancers.

Guardant Health, Inc.

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. It develops T-cell therapies for solid tumors and has reported responses in multiple solid tumor indications. Its platform helps to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. Its cell therapy candidates include genetically engineered T-cell receptors (TCRs) and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Its MAGE-A4 cell therapy franchise includes T-cell therapy products targeting solid tumor indications in which the MAGE-A4 antigen is expressed, with responses seen in eight indications (head and neck, esophagogastric junction, non-small cell lung cancer-squamous, synovial sarcoma, melanoma, urothelial, ovarian and myxoid/round cell liposarcoma indications).

Adaptimmune Therapeutics plc

Denali Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company’s clinical-stage programs include Antibody Transport Vehicle (ATV): triggering receptors expressed on myeloid cells 2 (TREM2), Protein Transport Vehicle (PTV): progranulin (PGRN), eukaryotic initiation factor 2 B (eIF2B), receptor-interacting serine/threonine protein kinase 1 (RIPK1), Enzyme Transport Vehicle (ETV): iduronate 2-sulfatase (IDS) and leucine-rich repeat kinase 2 (LRRK2), which are in various Phases ranging from Phase I through Phase III. The Company’s product candidates include DNL310, TAK-594/DNL593, TAK-920/DNL919, BIIB122/DNL151, DNL343, SAR443820/DNL788 and SAR443122/DNL758. The Company engineers its product candidates to cross the BBB, and act directly in the brain.

Denali Therapeutics Inc

iShares Core S&P 500 ETF (the Fund) is an exchange-traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Standard & Poor’s 500 Index (the Index). The Index measures the performance of the large-capitalization sector of the United States equity market. The component stocks are weighted according to the total float-adjusted market value of their outstanding shares. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Fund invests in sectors, such as consumer non-cyclical, financial, energy, technology, communications, industrial, consumer cyclical, basic materials and utilities. BlackRock Fund Advisors (BFA) serves as the investment advisor to the Fund.

Core S&P 500 iShares ETF

Vanguard 500 Index Fund (the Fund) is an open-end investment company, or mutual fund. The Fund offers four classes of shares: Investor Shares, Admiral Shares, Signal Shares, and Exchange Traded Fund (ETF) Shares. The Fund seeks to track the investment performance of the Standard & Poor’s 500 Index, an unmanaged benchmark representing the United States large-capitalization stocks. The Fund employs a passive management-or indexing-investment approach designed to track the performance of the Standard & Poor’s 500 Index. The Fund attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index. 

S&P 500 Vanguard ETF

Tesla, Inc. designs, develops, manufactures, sells and leases fully electric vehicles and energy generation and storage systems, and offer services related to its products. The Company's automotive segment includes the design, development, manufacturing, sales, and leasing of electric vehicles as well as sales of automotive regulatory credits. Additionally, the automotive segment is also comprised of services and other, which includes non-warranty after-sales vehicle services, sales of used vehicles, retail merchandise, sales by its acquired subsidiaries to third party customers, and vehicle insurance. Its energy generation and storage segment include the design, manufacture, installation, sales and leasing of solar energy generation and energy storage products and related services and sales of solar energy systems incentives. Its automotive products include Model 3, Model Y, Model S and Model X. Powerwall and Megapack are its lithium-ion battery energy storage products.

Tesla, Inc.

Apple Inc. (Apple) designs, manufactures and markets smartphones, personal computers, tablets, wearables and accessories and sells a range of related services. The Company’s products include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, HomePod, iPod touch and accessories. The Company operates various platforms, including the App Store, which allows customers to discover and download applications and digital content, such as books, music, video, games and podcasts. Apple offers digital content through subscription-based services, including Apple Arcade, Apple Music, Apple News+, Apple TV+ and Apple Fitness+. Apple also offers a range of other services, such as AppleCare, iCloud, Apple Card and Apple Pay. Apple sells its products and resells third-party products in a range of markets, including directly to consumers, small and mid-sized businesses, and education, enterprise and government customers through its retail and online stores and its direct sales force.

Apple, Inc.

Microsoft Corporation is a technology company. The Company develops and supports software, services, devices, and solutions. Its segments include Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment consists of products and services in its portfolio of productivity, communication, and information services, spanning a variety of devices and platforms. This segment includes Office Consumer, LinkedIn, Dynamics business solutions, and Office Commercial. The Intelligent Cloud segment consists of its public, private, and hybrid server products and cloud services. This segment includes server products and cloud services, and enterprise services. The More Personal Computing segment consists of products and services, such as Windows, devices, gaming, and search and news advertising.

Microsoft Corporation

Vanguard Information Technology ETF seeks to track the investment performance of the MSCI US Investable Market Information Technology 25/50 Index, a benchmark of large-, mid-, and small-cap United States stocks in the information technology sector, as classified under the Global Industry Classification Standard (GICS). This GICS sector is made up of companies in three areas: technology software and services, including companies that develop software in various fields (such as the Internet, applications, systems, databases, and/or home entertainment), and companies that provide information technology consulting and services, data processing, and outsourced services; technology hardware and equipment, including manufacturers and distributors of communications equipment, computers and peripherals and electronic equipment, and semiconductors and semiconductor equipment manufacturers. The Vanguard Group, Inc. serves as advisor to the Fund through its Quantitative Equity Group.

Back

Compare US

Compare AXNX vs. IVV

Overview

Performance

Industry & Region

Top Holdings

Industry & Region

Country Exposure

Industry Exposure